Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary

Pulse Biosciences, Inc. (PLSE) to Present at 35th Annual Piper Sandler Healthcare Conference

Positive

• Pulse Biosciences, Inc. will be presenting at the 35th Annual Piper Sandler Healthcare Conference, showcasing its CellFX Nanosecond Pulsed Field Ablation technology for atrial fibrillation treatment.
• The live and archived webcast of the presentation will be available on the company's website, offering accessibility to a wider audience and potential investors.

Negative

• None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35^th Annual Piper Sandler Healthcare Conference in New York.

Management is scheduled to present on Wednesday, November 29, 2023 at 8:10am ET. A live and archived webcast of the presentation will be available following the event on the “Investors” section of the company’s website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where CellFX nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231115239704/en/

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

or

Gilmartin Group

Philip Trip Taylor

415.937.5406

philip@gilmartinir.com

Source: Pulse Biosciences, Inc.

FAQ

What is the focus of Pulse Biosciences, Inc. presentation at the 35th Annual Piper Sandler Healthcare Conference?

Pulse Biosciences, Inc. will primarily focus on its CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation.

When and where will the presentation take place?

The presentation is scheduled for Wednesday, November 29, 2023, at 8:10am ET in New York.

Where can I access the webcast of the presentation?

The live and archived webcast will be available on the 'Investors' section of the company’s website at http://investors.pulsebiosciences.com/.